- Clinical Trials
- Research News
- Industry Trends
- Agency Actions
- Drug Safety Issues
- Approvals, Launches, & New Indications
- Health Care Reform
Cardiovascular Researchers Investigate New Interventional Technology for CAD
Drug-eluting, bioresorbable scaffold provides support to heart vessels (Jan. 8)
A new cardiac interventional device that dissolves after opening blocked arteries is being evaluated in a national research study led by clinical investigators at the Christ Hospital in Cincinnati, Ohio.
Absorb BVS (Abbott) is a drug-eluting, bioresorbable vascular scaffold for the treatment of coronary artery disease (CAD). The tiny mesh tubular device is composed of polylactide — a biocompatible material commonly used in medical implants, such as dissolvable sutures. The scaffold provides transient support to the heart vessel until normal functioning is restored and then dissolves naturally over time.
A randomized, controlled trial — ABSORB III — will enroll approximately 2,250 patients, the majority in the U.S. The study is designed to compare the performance of Absorb BVS with that of traditional metal, drug-eluting stents. Data collected from this trial will support U.S. regulatory filings for the new device.
Absorb BVS is available for sale in Europe and parts of Asia and Latin America but not in the U.S., where it is limited to investigational use.
Source: Christ Hospital; January 8, 2013.